Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non–small cell lung cancer

Slides:

Advertisements

Similar presentations

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Advertisements

Manuel J. Antunes, MD, PhD, DSc

High-mobility group box-1 protein induces osteogenic phenotype changes in aortic valve interstitial cells Bo Wang, PhD, Fei Li, MD, Chao Zhang, PhD,

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies Ali Mahtabifard,

Dimethyl celecoxib as a novel non–cyclooxygenase 2 therapy in the treatment of non– small cell lung cancer Leah M. Backhus, MD, Nicos A. Petasis, PhD,

Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: Role in non–small cell lung cancer tumor proliferation

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Effects of azithromycin and tanomastat on experimental bronchiolitis obliterans Katharina Krenn, MD, Matthias Gmeiner, MD, PhD, Patrick Paulus, MD, Nezir.

Exogenous surfactant attenuation of ischemia–reperfusion injury in the lung through alteration of inflammatory and apoptotic factors Bart P. van Putte,

Lung cancer screening: No more excuses

Postmortem and ex vivo carbon monoxide ventilation reduces injury in rat lungs transplanted from non–heart-beating donors Boming Dong, MD, PhD, Paul.

Interventional radiology suite or hybrid operating room: Which is the best for lung nodule localization? Robert B. Cameron, MD The Journal of Thoracic.

Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo

Amine Mazine, MD, MSc, Subodh Verma, MD, PhD, Bobby Yanagawa, MD, PhD

Survival after resection of synchronous non–small cell lung cancer

Intrinsic cardiac stem cells are essential for regeneration

Abracadabra I, II…HeartMate 3?

Victor van Berkel, MD, PhD

Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma Costanzo A. DiPerna, MD,

Primary pulmonary meningioma: Ten-year follow-up findings for a multiple case, implying a benign biological nature Yukitoshi Satoh, Yuichi Ishikawa

Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation Yosuke Tanaka, MD, Tomomi Hasegawa, MD, PhD,

Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines:

The lord of the rings Antonio Miceli, MD, PhD

Is tissue the issue? Brian E. Louie, MD, MHA, MPH, FRCSC, FACS

Gastric conduit revision after esophagectomy: The raising of Lazarus

STAT3, Cten, and lung cancer: Simultaneous excitement and caution

Yang Zhang, MD, Haiquan Chen, MD, PhD

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

A first start for lung transplantation?

Demonstration of persistent tumor cells 4 weeks after radiofrequency ablation of a pulmonary adenocarcinoma Stéphane Renaud, Marco Schiavon, MD, Nicola.

Jules Lin, MD The Journal of Thoracic and Cardiovascular Surgery

Get it right the first time

Navigating the lung for hidden treasure

Joseph A. Dearani, MD, Michael J. Ackerman, MD, PhD

Yusuke Takahashi, MD, PhD, Prasad S. Adusumilli, MD

Historical perspectives of The American Association for Thoracic Surgery: Robert M. Janes, MD ( ) Myunghyun Lee, MD, Vivek Rao, MD, PhD The.

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

CD4+ T lymphocytes mediate acute pulmonary ischemia–reperfusion injury

Attachment disorder in thoracoabdominal surgery

Uma M. Sachdeva, MD, PhD, Daniela Molena, MD

The Ross procedure: Time to reevaluate the guidelines

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

We are the company we keep: The importance of the tumor microenvironment Sai Yendamuri, MD, FACS The Journal of Thoracic and Cardiovascular Surgery

Cardiac myxoma: Simplifying a “complex” case

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Saving the esophagus: At what cost?

First nights, the adrenal axis, and steroids

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

Bryan M. Burt, MD The Journal of Thoracic and Cardiovascular Surgery

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

The future of cardiac surgery training: A survival guide

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Ralph E. Delius, MD The Journal of Thoracic and Cardiovascular Surgery

“The more things change…”: The challenges ahead

Why arch curvature affects arch resistance

Managing conflicts of interest

Aritoshi Hattori, MD, Kenji Suzuki, MD

Lung cancer randomized controlled trials should compare stereotactic body radiation therapy with observation, NOT surgery Raja M. Flores, MD The Journal.

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Did you like Terminator 3 better than Terminator 2

Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Non–Small- Cell Lung Cancer Cheng-Yi Wang, MD, Ting-Ting Chao, PhD, Wei-Tien.

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Calpain inhibitors: The aspirin of the 21st century?

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Presentation transcript:

Perioperative cyclooxygenase 2 inhibition to reduce tumor cell adhesion and metastatic potential of circulating tumor cells in non–small cell lung cancer Leah M. Backhus, MD, Eric Sievers, MD, Gloria Y. Lin, MD, Roberto Castanos, Robert D. Bart, MD, Vaughn A. Starnes, MD, Ross M. Bremner, MD, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 132, Issue 2, Pages 297-303 (August 2006) DOI: 10.1016/j.jtcvs.2005.10.060 Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Tumor metastasis in murine model. A, Means (bars) and SDs (error bars) of number of tumor foci, as counted by a blinded observer, for each group. Asterisk indicates P < .05 versus control. B, Gross specimens depicting surface tumor nodules for control (A1), perioperative treatment (A2), and continuous treatment (A3) groups at 6 weeks from injection. C, Histologic examination (hematoxylin and eosin) with COX-2 immunohistochemical counterstain shows tumor nodules within lung parenchyma for control (A1), perioperative treatment (A2), and continuous treatment (A3) groups. COX-2 stains are shown to illustrate tumor nodules more clearly and to show continued expression of protein despite COX-2 inhibition. COX-2 inhibitors are enzyme blockers and do not predictably affect either messenger RNA or transcription of protein. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 297-303DOI: (10.1016/j.jtcvs.2005.10.060) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Graph representing tumor cell adhesion to Matrigel ECM depicts decreased ability of cells to attach when treated with celecoxib. DMSO, Dimethyl sulfoxide; hpf, high-power field. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 297-303DOI: (10.1016/j.jtcvs.2005.10.060) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions

Figure 3 Western blot for CD44. IL-1β increased expression of CD44. Celecoxib (Cel) decreased expression of CD44, even after IL-1β stimulation. DMSO, Dimethyl sulfoxide. The Journal of Thoracic and Cardiovascular Surgery 2006 132, 297-303DOI: (10.1016/j.jtcvs.2005.10.060) Copyright © 2006 The American Association for Thoracic Surgery Terms and Conditions